Shares of Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) were up 0.6% on Thursday . The stock traded as high as C$1.91 and last traded at C$1.70. Approximately 102,231 shares were traded during trading, a decline of 5% from the average daily volume of 107,412 shares. The stock had previously closed at C$1.69.
Medicenna Therapeutics Trading Up 0.6 %
The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.65 and a current ratio of 2.51. The firm has a market capitalization of C$129.93 million, a price-to-earnings ratio of -4.47 and a beta of 1.21. The company has a 50 day moving average price of C$2.16 and a two-hundred day moving average price of C$2.19.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
See Also
- Five stocks we like better than Medicenna Therapeutics
- What Are Growth Stocks and Investing in Them
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- The Most Important Warren Buffett Stock for Investors: His Own
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
